Patents by Inventor Jennifer Leslie Harris
Jennifer Leslie Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200306244Abstract: The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also provides a method for the treatment of fibrosis, a pharmaceutical combination comprising a wnt inhibitor of formula (I) and a second active ingredient for use in the treatment of fibrosis and also the use of a wnt inhibitor of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of fibrosis and fibrosis mediated disorders.Type: ApplicationFiled: June 20, 2017Publication date: October 1, 2020Applicant: Novartis AGInventors: Jennifer Leslie HARRIS, Peter GERGELY, Jun LIU, Eric SVENSSON
-
COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES
Publication number: 20180318305Abstract: The present invention relates to a pharmaceutical combination comprising, separately or together, (1) a first agent which is an ALK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof. The invention further relates the use of such combination in the treatment or prevention of proliferative diseases.Type: ApplicationFiled: July 16, 2018Publication date: November 8, 2018Inventors: Jennifer Leslie Harris, Nanxin Li, Timothy R Smith, Yael Mosse, Andrew Wood -
COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES
Publication number: 20160361314Abstract: The present invention relates to a pharmaceutical combination comprising, separately or together, (1) a first agent which is an ALK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof. The invention further relates the use of such combination in the treatment or prevention of proliferative diseases.Type: ApplicationFiled: August 28, 2014Publication date: December 15, 2016Applicant: Novartis AGInventors: Jennifer Leslie HARRIS, Nanxin LI, Timothy R SMITH, Yael MOSSE, Andrew WOOD -
Patent number: 8703787Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.Type: GrantFiled: February 2, 2012Date of Patent: April 22, 2014Assignee: IRM LLCInventors: Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
-
Publication number: 20130296357Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.Type: ApplicationFiled: February 2, 2012Publication date: November 7, 2013Applicant: IRM LLCInventors: Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
-
Publication number: 20120208882Abstract: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: February 14, 2012Publication date: August 16, 2012Inventors: Henry Luke Danahay, Darren Mark LeGrand, David C. Tully, Jennifer Leslie Harris, Silvia Heuerding, Dilraj Singh, Janet Catherine Maas, Juergen Roettele, Jean-Louis Reber, Stéphanie Monnier
-
Publication number: 20090203777Abstract: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 12, 2006Publication date: August 13, 2009Inventors: Henry Luke Danahay, Darren Mark Legrand, David C. Tully, Jennifer Leslie Harris, Silvia Heuerding, Dilraj Singh, Janet Catherine Maas, Juergen Roettele, Jean-Louis Reber, Stephanie Monnier
-
Publication number: 20080242671Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.Type: ApplicationFiled: March 25, 2008Publication date: October 2, 2008Applicant: IRM LLCInventors: Hong Liu, Phillip Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li
-
Patent number: 7384970Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.Type: GrantFiled: March 23, 2004Date of Patent: June 10, 2008Assignee: IRM LLCInventors: Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li
-
Patent number: 7109243Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.Type: GrantFiled: March 23, 2004Date of Patent: September 19, 2006Assignee: IRM LLCInventors: Hong Liu, David Tully, Robert Epple, Badry Bursulaya, Jennifer Williams, Arnab Chatterjee, Jennifer Leslie Harris, Jun Li
-
Publication number: 20040248887Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.Type: ApplicationFiled: March 23, 2004Publication date: December 9, 2004Applicant: IRM LLCInventors: Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li
-
Publication number: 20040198780Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.Type: ApplicationFiled: March 23, 2004Publication date: October 7, 2004Applicant: IRM LLCInventors: Hong Liu, David Tully, Robert Epple, Badry Bursulaya, Jennifer Williams, Arnab Chatterjee, Jennifer Leslie Harris, Jun Li
-
Publication number: 20040009911Abstract: Substrate specificity profiles are used to determine optimal hepsin substrate sequences, both to the prime side and non-prime side of the hepsin recognition site. The hepsin substrate sequences are used in designing substrates, inhibitors, and prodrugs. For example, prodrugs are provided for use in the treatment of prostate cancer. Hepsin inhibitors based on substrate specificity are also provided.Type: ApplicationFiled: January 31, 2003Publication date: January 15, 2004Applicant: IRM, LLCInventors: Jennifer Leslie Harris, Bradley J. Backes, Jun Li, David C. Tully
-
Publication number: 20030059847Abstract: Non-peptide protease substrate libraries and high purity protease substrate libraries are constructed, e.g., using fluorogenic compounds. The libraries are useful in obtaining substrate profiles for a variety of proteases, such as methods for determining both prime and non-prime protease recognition sequences.Type: ApplicationFiled: August 27, 2002Publication date: March 27, 2003Applicant: IRM, LLCInventors: Bradley J. Backes, Jennifer Leslie Harris